Lexicon Pharmaceuticals (LXRX) Invested Capital (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Invested Capital data on file, last reported at $202.9 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $202.9 million, up 22.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $202.9 million (up 22.88% YoY), and the FY2025 annual result was $112.1 million, down 23.17% from the prior year.
• Invested Capital grew to $202.9 million in Q1 2026 per LXRX's latest filing, from $112.1 million in the prior quarter.
• Over five years, Invested Capital peaked at $288.9 million in Q1 2024 and troughed at $93.1 million in Q4 2023.
• A 5-year average of $169.5 million and a median of $165.1 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2025: Invested Capital soared 201.98% in 2023, then slumped 46.06% in 2025.
• A 5-year view of Invested Capital shows it stood at $165.7 million in 2022, then tumbled by 43.82% to $93.1 million in 2023, then surged by 56.75% to $146.0 million in 2024, then declined by 23.17% to $112.1 million in 2025, then jumped by 80.91% to $202.9 million in 2026.
• Business Quant data shows LXRX's Invested Capital at $202.9 million in Q1 2026, $112.1 million in Q4 2025, and $120.2 million in Q3 2025.